NASDAQ: ME23andme Holding Co Stock
$0.46-0.01 (-2.13%)
Updated Apr 25, 2024
ME Price
$0.46
Fair Value Price
N/A
Market Cap
$221.66M
52 Week Low
$0.35
52 Week High
$2.21
P/E
-0.41x
P/B
0.59x
P/S
1.77x
PEG
N/A
Dividend Yield
N/A
Revenue
$247.99M
Earnings
-$521.97M
Gross Margin
45.3%
Operating Margin
-210.72%
Profit Margin
-210.5%
Debt to Equity
0.61
Operating Cash Flow
-$183M
Beta
1.68
Next Earnings
May 26, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ME Overview
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ME scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ME is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ME is good value based on its book value relative to its share price (0.59x), compared to the US Diagnostics & Research industry average (4.15x)
P/B vs Industry Valuation
ME is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ME due diligence checks available for Premium users.
Be the first to know about important ME news, forecast changes, insider trades & much more!
ME News
Valuation
ME price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.41x
Industry
38.32x
Market
40.97x
ME price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.59x
Industry
4.15x
ME is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ME's financial health
Profit margin
Revenue
$44.7M
Net Income
-$278.0M
Profit Margin
-621.2%
ME's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ME's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$608.2M
Liabilities
$231.0M
Debt to equity
0.61
ME's short-term assets ($309.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ME's short-term assets ($309.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ME's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.1M
Investing
-$2.0M
Financing
$105.0k
ME's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ME vs Diagnostic & Research Stocks
23andme Holding Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.